Once again, the Mainz-based company BioNTech has secured a sum in the hundred-million-euro range. Two thirds of the capital was contributed by new investors.
BioNTech SE announces the start of clinical development for its drug candidate DuoBody PD-L1x4-1BB.
With the help of investors both new and old, the Freiburg-based start-up is taking the next big step in the introduction of its innovative technology for the rapid detection of multi-resi
The "vaccination against tick bites" of the Norden Vaccines team is among the winners of the Innovation Prize of the Bioregions of Germany 2019.
Rumors have it that BioNTech is preparing for an IPO on the US technology exchange Nasdaq. According to Reuters, the company has entrusted two US banks with the preparations.